51. Therapy of mucosal candidiasis by expression of an anti-idiotype in human commensal bacteria.
- Author
-
Beninati C, Oggioni MR, Boccanera M, Spinosa MR, Maggi T, Conti S, Magliani W, De Bernardis F, Teti G, Cassone A, Pozzi G, and Polonelli L
- Subjects
- Administration, Intravaginal, Animals, Anti-Bacterial Agents, Anti-Infective Agents administration & dosage, Anti-Infective Agents immunology, Anti-Infective Agents therapeutic use, Antifungal Agents pharmacology, Antifungal Agents therapeutic use, Candida albicans drug effects, Candida albicans physiology, Candidiasis immunology, Candidiasis microbiology, Colony Count, Microbial, Disease Models, Animal, Female, Fluconazole pharmacology, Fluconazole therapeutic use, Humans, Immunization, Passive, Immunoglobulin Idiotypes administration & dosage, Immunoglobulin Idiotypes genetics, Mycotoxins administration & dosage, Mycotoxins chemistry, Mycotoxins immunology, Mycotoxins therapeutic use, Protein Engineering, Rats, Recombinant Proteins administration & dosage, Recombinant Proteins genetics, Recombinant Proteins immunology, Recombinant Proteins therapeutic use, Streptococcus cytology, Streptococcus physiology, Vaginitis immunology, Vaginitis microbiology, Candida albicans immunology, Candidiasis therapy, Immunoglobulin Idiotypes immunology, Immunoglobulin Idiotypes therapeutic use, Streptococcus genetics, Vaginitis therapy
- Abstract
Two recombinant strains of Streptococcus gordonii, secreting or displaying a microbicidal single-chain antibody (H6), and stably colonizing rat vagina, were used to treat an experimental vaginitis caused by Candida albicans. A post-challenge intravaginal delivery of the H6-secreting strain was as efficacious as fluconazole in rapidly abating the fungal burden. Three weeks after challenge, 75% and 37.5% of the rats treated with the H6-secreting or displaying bacteria, respectively, were cured of the infection, which persisted in 100% of the animals treated with a S. gordonii strain expressing an irrelevant single-chain antibody. Thus, a human commensal bacterium can be suitably engineered to locally release a therapeutic antibody fragment.
- Published
- 2000
- Full Text
- View/download PDF